01.05.2011
LUX-Lung 2 is a multicentre Phase II, randomised, open-label, single arm trial of afatinib* in patients with advanced lung cancer that were untreated or progressed after one course of chemotherapy. Patients were tested for activating EGFR mutations prior to their inclusion in the trial.
